Company / Cash & Equivalents
Vaxart, Inc. Cash & Equivalents History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$63.8M
FY2025
5-year range
$1.6M / $63.8M
FY2021-FY2025
Trend
+23.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has increased for 3 consecutive years, from $2M in FY2017 to $64M in FY2025.
Based on SEC 10-K filings.
$64M in FY2025 with a 10-year CAGR of +3.6%.
Improved from $12M to $64M over the past 7 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +3.6%
Key checks
Key Insights
- Vaxart, Inc.'s cash & equivalents has grown for 3 consecutive years.
- In FY2025, cash & equivalents increased 23.4% year-over-year.
- Peak cash & equivalents was recorded in FY2014.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.04 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $63.8M | +23.4% |
| FY2024 | $51.7M | +349.3% |
| FY2018 | $11.5M | +632.4% |
| FY2017 | $1.6M | -81.3% |
| FY2016 | $8.4M | -81.2% |
| FY2015 | $44.7M | -45.3% |
| FY2014 | $81.7M | +22.3% |
| FY2013 | $66.8M | -10.0% |
| FY2011 | $74.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026